ReP USP - Resultado da busca

Artigo de periodico
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022)
Furtado, Remo H. M.; Raz, Itamar; Goodrich, Erica L.; Murphy, Sabina A.; Bhatt, Deepak L.; Leiter, Lawrence A.; Mcguire, Darren K.; Wilding, John P. H.; Aylward, Philip; Dalby, Anthony J.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: HIPERTENSÃO, INSUFICIÊNCIA CARDÍACA, DIABETES MELLITUS, RESULTADO DE TRATAMENTO, FÁRMACOS (SISTEMA CARDIOVASCULAR)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M. et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.058103. Acesso em: 10 nov. 2024.
APA
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 145( 21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103
NLM
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Vancouver
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Artigo de periodico
Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health REACH) Registry (2016)
Eisen, Alon; Bhatt, Deepak L.; Steg, Gabriel; Eagle, Kim A.; Goto, Shinya; Guo, Jianping; Smith, Sidney C.; Ohman, E. Magnus; Scirica, Benjamin; Maciel, Léa Maria Zanini; Pazin Filho, Antonio
Source: Journal of the American Heart Association - JAHA. Unidade: FMRP
Subjects: ANGINA PECTORIS, DOENÇAS CARDIOVASCULARES, CORONARIOPATIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EISEN, Alon et al. Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health REACH) Registry. Journal of the American Heart Association - JAHA, v. 5, n. 10, 2016Tradução . . Disponível em: https://doi.org/10.1161/JAHA.116.004080. Acesso em: 10 nov. 2024.
APA
Eisen, A., Bhatt, D. L., Steg, G., Eagle, K. A., Goto, S., Guo, J., et al. (2016). Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health REACH) Registry. Journal of the American Heart Association - JAHA, 5( 10). doi:10.1161/JAHA.116.004080
NLM
Eisen A, Bhatt DL, Steg G, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica B, Maciel LMZ, Pazin Filho A. Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health REACH) Registry [Internet]. Journal of the American Heart Association - JAHA. 2016 ; 5( 10):[citado 2024 nov. 10 ] Available from: https://doi.org/10.1161/JAHA.116.004080
Vancouver
Eisen A, Bhatt DL, Steg G, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica B, Maciel LMZ, Pazin Filho A. Angina and future cardiovascular events in stable patients with coronary artery disease: Insights from the Reduction of Atherothrombosis for Continued Health REACH) Registry [Internet]. Journal of the American Heart Association - JAHA. 2016 ; 5( 10):[citado 2024 nov. 10 ] Available from: https://doi.org/10.1161/JAHA.116.004080
Artigo de periodico
Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial (2016)
Lopes, Renato D.; Leonardi, Sergio; Neely, Benjamin; Neely, Megan L.; Ohman, E. Magnus; Ardissino, Diego; Hamm, Christian W.; Goodman, Shaun G.; Bhatt, Deepak L.; White, Harvey D.; Prabhakaran, Dorairaj; Martinez, Felipe; Nicolau, Jose C.; Winters, Kenneth J.; Fox, Keith A. A.; Armstrong, Paul W.; Roe, Matthew T.
Source: Journal of the American College of Cardiology. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, FÁRMACOS (SISTEMA CARDIOVASCULAR), ESTUDOS RANDOMIZADOS, REVASCULARIZAÇÃO MIOCÁRDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Renato D. et al. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Journal of the American College of Cardiology, v. 67, n. 11, p. 1289-1297, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2016.01.034. Acesso em: 10 nov. 2024.
APA
Lopes, R. D., Leonardi, S., Neely, B., Neely, M. L., Ohman, E. M., Ardissino, D., et al. (2016). Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Journal of the American College of Cardiology, 67( 11), 1289-1297. doi:10.1016/j.jacc.2016.01.034
NLM
Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KAA, Armstrong PW, Roe MT. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 11): 1289-1297.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.jacc.2016.01.034
Vancouver
Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KAA, Armstrong PW, Roe MT. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 11): 1289-1297.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.jacc.2016.01.034
Artigo de periodico
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease (2016)
Bonaca, Marc P.; Bhatt, Deepak L.; Storey, Robert F.; Steg, Gabriel; Cohen, Marc; Kuder, Julia; Goodrich, Erica; Nicolau, José C.; Parkhomenko, Alexander; López-Sendón, José; Dellborg, Mikael; Dalby, Anthony; Špinar, Jindřich; Aylward, Philip; Corbalán, Ramón; Abola, Maria Teresa B.; Jensen, Eva C.; Held, Peter; Braunwald, Eugene; Sabatine Marc S.
Source: Journal of the American College of Cardiology. Unidade: FM
Subjects: PLACEBO, FÁRMACOS (SISTEMA CARDIOVASCULAR), DOENÇAS CARDIOVASCULARES, REVASCULARIZAÇÃO MIOCÁRDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONACA, Marc P. et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, v. 67, n. 23, p. 2719-2728, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2016.03.524. Acesso em: 10 nov. 2024.
APA
Bonaca, M. P., Bhatt, D. L., Storey, R. F., Steg, G., Cohen, M., Kuder, J., et al. (2016). Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 67( 23), 2719-2728. doi:10.1016/j.jacc.2016.03.524
NLM
Bonaca MP, Bhatt DL, Storey RF, Steg G, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine Marc S. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 23): 2719-2728.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.jacc.2016.03.524
Vancouver
Bonaca MP, Bhatt DL, Storey RF, Steg G, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine Marc S. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 23): 2719-2728.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.jacc.2016.03.524
Artigo de periodico
Long-term use of ticagrelor in patients with prior myocardial infarction (2015)
Bonaca, Marc P.; Bhatt, Deepak L.; Cohen, Marc; Steg, Philippe Gabriel; Storey, Robert F.; Jensen, Eva C.; Magnani, Giulia; Bansilal, Sameer; Fish, M. Polly; Im, Kyungah; Bengtsson, Olof; Ophuis, Ton Oude; Budaj, Andrzej; Theroux, Pierre; Ruda, Mikhail; Hamm, Christian; Goto, Shinya; Spinar, Jindrich; Nicolau, José Carlos; Kiss, Robert G.; Murphy, Sabina A.; Wiviott, Stephen D.; Held, Peter; Braunwald, Eugene; Sabatine, Marc S.; Marin Neto, José Antonio
Source: The New England Journal of Medicine. Unidades: FM, FMRP
Subjects: FATORES DE RISCO, INFARTO DO MIOCÁRDIO, ADESÃO À MEDICAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONACA, Marc P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. The New England Journal of Medicine, v. 372, n. 19, 2015Tradução . . Disponível em: http://link.periodicos.capes.gov.br/sfxlcl41?url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&ctx_enc=info:ofi/enc:UTF-8&ctx_ver=Z39.88-2004&rfr_id=info:sid/sfxit.com:azlist&sfx.ignore_date_threshold=1&rft.object_id=954925428260. Acesso em: 10 nov. 2024.
APA
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., et al. (2015). Long-term use of ticagrelor in patients with prior myocardial infarction. The New England Journal of Medicine, 372( 19). doi:10.1056/NEJMoa1500857
NLM
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, Marin Neto JA. Long-term use of ticagrelor in patients with prior myocardial infarction [Internet]. The New England Journal of Medicine. 2015 ; 372( 19):[citado 2024 nov. 10 ] Available from: http://link.periodicos.capes.gov.br/sfxlcl41?url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&ctx_enc=info:ofi/enc:UTF-8&ctx_ver=Z39.88-2004&rfr_id=info:sid/sfxit.com:azlist&sfx.ignore_date_threshold=1&rft.object_id=954925428260
Vancouver
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, Marin Neto JA. Long-term use of ticagrelor in patients with prior myocardial infarction [Internet]. The New England Journal of Medicine. 2015 ; 372( 19):[citado 2024 nov. 10 ] Available from: http://link.periodicos.capes.gov.br/sfxlcl41?url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&ctx_enc=info:ofi/enc:UTF-8&ctx_ver=Z39.88-2004&rfr_id=info:sid/sfxit.com:azlist&sfx.ignore_date_threshold=1&rft.object_id=954925428260
Artigo de periodico
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial (2015)
Udell, Jacob A.; Bhatt, Deepak L.; Braunwald, Eugene; Cavender, Matthew A.; Mosenzon, Ofri; Steg, Gabriel; Davidson, Jaime A.; Nicolau, Jose C.; Corbalan, Ramon; Hirshberg, Boaz; Frederich, Robert; Im, KyungAh; Umez-Eronini, Amarachi A.; He, Ping; McGuire, Darren K.; Leiter, Lawrence A.; Raz, Itamar; Scirica, Benjamin M.
Source: Diabetes Care. Unidade: FM
Subjects: DIABTES MELLITUS (COMPLICAÇÕES), FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, INIBIDORES DE ENZIMAS, NEOPLASIAS (ETIOLOGIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
UDELL, Jacob A. et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, v. 38, n. 4, p. 696-705, 2015Tradução . . Disponível em: https://doi.org/10.2337/dc14-1850. Acesso em: 10 nov. 2024.
APA
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, G., et al. (2015). Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 38( 4), 696-705. doi:10.2337/dc14-1850
NLM
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2024 nov. 10 ] Available from: https://doi.org/10.2337/dc14-1850
Vancouver
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2024 nov. 10 ] Available from: https://doi.org/10.2337/dc14-1850
Artigo de periodico
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial (2015)
Nicolau, Jose Carlos; Bhatt, Deepak L.; Roe, Matthew T.; Lokhnygina, Yuliya; Neely, Benjamin; Corbalán, Ramón; Leiva-Pons, José L.; Martinez, Felipe; Goodman, Shaun G.; Winters, Kenneth J.; Verheugt, Freek W.A.; Armstrong, Paul W.; White, Harvey D.; Fox, Keith A. A.; Prabhakaran, Dorairaj; Ohman, E. Magnus
Source: American Heart Journal. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, MEDICAMENTO (ADMINISTRAÇÃO E DOSAGEM), ADMINISTRAÇÃO DOS CUIDADOS AO PACIENTE, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, Jose Carlos et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, v. 170, n. 4, p. 683-694, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2015.05.017. Acesso em: 10 nov. 2024.
APA
Nicolau, J. C., Bhatt, D. L., Roe, M. T., Lokhnygina, Y., Neely, B., Corbalán, R., et al. (2015). Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, 170( 4), 683-694. doi:10.1016/j.ahj.2015.05.017
NLM
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Vancouver
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Trabalho de evento-resumo periodico
Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial (2013)
Lopes, Renato D.; Neely, Benjamin; Ohman, E. M.; Ardissino, Diego; Hamm, Christian; Goodman, Shaun G.; Bhatt, Deepak L.; Brown, Eileen B.; White, Harvey D.; Prabhakaran, Dorairaj; Martinez, Felipe; Nicolau, Jose C.; Fox, Keith A.; Armstrong, Paul W.; Roe, Matthew T.
Source: Circulation. Conference titles: American Heart Associations of the Scientific Sessions and Resuscitation Science Symposium. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, MEDICAMENTO, SÍNDROME CORONARIANA AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Renato D. et al. Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A14972?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4. Acesso em: 10 nov. 2024. , 2013
APA
Lopes, R. D., Neely, B., Ohman, E. M., Ardissino, D., Hamm, C., Goodman, S. G., et al. (2013). Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A14972?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4
NLM
Lopes RD, Neely B, Ohman EM, Ardissino D, Hamm C, Goodman SG, Bhatt DL, Brown EB, White HD, Prabhakaran D, Martinez F, Nicolau JC, Fox KA, Armstrong PW, Roe MT. Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2024 nov. 10 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A14972?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4
Vancouver
Lopes RD, Neely B, Ohman EM, Ardissino D, Hamm C, Goodman SG, Bhatt DL, Brown EB, White HD, Prabhakaran D, Martinez F, Nicolau JC, Fox KA, Armstrong PW, Roe MT. Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2024 nov. 10 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A14972?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4
Trabalho de evento-resumo periodico
The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial (2013)
O'Donoghue, Michelle L.; Mega, Jessica L.; Braunwald, Eugene; Nicolau, Jose C.; Bhatt, Deepak L.; Murphy, Sabina A.; Gibson, C. Michael
Source: Circulation. Conference titles: American Heart Associations of the Scientific Sessions and Resuscitation Science Symposium. Unidade: FM
Subjects: MEDICAMENTO, ANTICOAGULANTES, SÍNDROME CORONARIANA AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
O'DONOGHUE, Michelle L. et al. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4. Acesso em: 10 nov. 2024. , 2013
APA
O'Donoghue, M. L., Mega, J. L., Braunwald, E., Nicolau, J. C., Bhatt, D. L., Murphy, S. A., & Gibson, C. M. (2013). The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4
NLM
O'Donoghue ML, Mega JL, Braunwald E, Nicolau JC, Bhatt DL, Murphy SA, Gibson CM. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2024 nov. 10 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4
Vancouver
O'Donoghue ML, Mega JL, Braunwald E, Nicolau JC, Bhatt DL, Murphy SA, Gibson CM. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2024 nov. 10 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4
Artigo de periodico
Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors (2013)
Barthélémy, Olivier; Limbourg, Tobias; Collet, Jean Philippe; Beygui, Farzin; Silvain, Johanne; Bellemain-Appaix, Anne; Cayla, Guillaume; Chastre, Thomas; Baumgartner, Iris; Röther, Joachim; Zeymer, Uwe; Bhatt, Deepak L.; Steg, Gabriel; Montalescot, Gilles; Pazin Filho, Antonio; Maciel, Léa Maria Zanini
Source: International Journal of Cardiology. Unidade: FMRP
Subjects: ANTI-INFLAMATÓRIOS NÃO ESTEROIDES, INFARTO DO MIOCÁRDIO, ACIDENTE VASCULAR CEREBRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARTHÉLÉMY, Olivier et al. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. International Journal of Cardiology, v. 163, n. 3, p. 266-271, 2013Tradução . . Disponível em: https://doi.org/10.1016/j.ijcard.2011.06.015. Acesso em: 10 nov. 2024.
APA
Barthélémy, O., Limbourg, T., Collet, J. P., Beygui, F., Silvain, J., Bellemain-Appaix, A., et al. (2013). Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. International Journal of Cardiology, 163( 3), 266-271. doi:10.1016/j.ijcard.2011.06.015
NLM
Barthélémy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain-Appaix A, Cayla G, Chastre T, Baumgartner I, Röther J, Zeymer U, Bhatt DL, Steg G, Montalescot G, Pazin Filho A, Maciel LMZ. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors [Internet]. International Journal of Cardiology. 2013 ; 163( 3): 266-271.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ijcard.2011.06.015
Vancouver
Barthélémy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain-Appaix A, Cayla G, Chastre T, Baumgartner I, Röther J, Zeymer U, Bhatt DL, Steg G, Montalescot G, Pazin Filho A, Maciel LMZ. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors [Internet]. International Journal of Cardiology. 2013 ; 163( 3): 266-271.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ijcard.2011.06.015
Artigo de periodico
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial (2013)
Feres, Fausto; Costa, Ricardo A.; Abizaid, Alexandre; Leon, Martin B.; Marin Neto , José Antonio; Botelho, Roberto V.; King, Spencer B.; Negoita, Manuela; Liu, Minglei; Paula, J. Eduardo T. de; Mangione, José A.; Meireles, George X.; Castello Júnior, Hélio J.; Nicolela Júnior, Eduardo L.; Perin, Marco A.; Devito, Fernando S.; Labrunie, André; Salvadori Júnior, Décio; Gusmão, Marcos; Staico, Rodolfo; Costa Júnior, J. Ribamar; Castro, Juliana P. de; Abizaid, Andrea S.; Bhatt, Deepak L.
Source: JAMA - Journal of The American Medical Association. Unidade: FMRP
Subjects: SÍNDROME CORONARIANA AGUDA (TERAPIA), TROMBOSE, PLAQUETAS SANGUÍNEAS, ANTICOAGULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERES, Fausto et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial. JAMA - Journal of The American Medical Association, v. 310, n. 23, p. 2510-2522, 2013Tradução . . Disponível em: https://doi.org/10.1001/jama.2013.282183. Acesso em: 10 nov. 2024.
APA
Feres, F., Costa, R. A., Abizaid, A., Leon, M. B., Marin Neto , J. A., Botelho, R. V., et al. (2013). Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial. JAMA - Journal of The American Medical Association, 310( 23), 2510-2522. doi:10.1001/jama.2013.282183
NLM
Feres F, Costa RA, Abizaid A, Leon MB, Marin Neto JA, Botelho RV, King SB, Negoita M, Liu M, Paula JET de, Mangione JA, Meireles GX, Castello Júnior HJ, Nicolela Júnior EL, Perin MA, Devito FS, Labrunie A, Salvadori Júnior D, Gusmão M, Staico R, Costa Júnior JR, Castro JP de, Abizaid AS, Bhatt DL. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial [Internet]. JAMA - Journal of The American Medical Association. 2013 ; 310( 23): 2510-2522.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1001/jama.2013.282183
Vancouver
Feres F, Costa RA, Abizaid A, Leon MB, Marin Neto JA, Botelho RV, King SB, Negoita M, Liu M, Paula JET de, Mangione JA, Meireles GX, Castello Júnior HJ, Nicolela Júnior EL, Perin MA, Devito FS, Labrunie A, Salvadori Júnior D, Gusmão M, Staico R, Costa Júnior JR, Castro JP de, Abizaid AS, Bhatt DL. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial [Internet]. JAMA - Journal of The American Medical Association. 2013 ; 310( 23): 2510-2522.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1001/jama.2013.282183
Artigo de periodico
Optimized duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (optimize) trial: rationale and designof a large-scale, randomized, multicenter study (2012)
Feres, Fausto; Costa, Ricardo A.; Bhatt, Deepak L.; Leon, Martin B.; Botelho, Roberto V.; King, Spencer B.; Paula, J. Eduardo T. de; Mangione, José A.; Salvadori Júnior, Décio; Gusmão, Marcos O.; Castello Júnior, Hélio; Nicolela Júnior, Eduardo; Perin, Marco A.; Devito, Fernando S.; Marin Neto, Jose Antonio; Abizaid, Alexandre
Source: American Heart Journal. Unidade: FMRP
Subjects: CORONARIOPATIA, ANTICOAGULANTES (APLICAÇÕES TERAPÊUTICAS), ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERES, Fausto et al. Optimized duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (optimize) trial: rationale and designof a large-scale, randomized, multicenter study. American Heart Journal, v. 164, n. 6, p. 810-816, 2012Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2012.09.009. Acesso em: 10 nov. 2024.
APA
Feres, F., Costa, R. A., Bhatt, D. L., Leon, M. B., Botelho, R. V., King, S. B., et al. (2012). Optimized duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (optimize) trial: rationale and designof a large-scale, randomized, multicenter study. American Heart Journal, 164( 6), 810-816. doi:10.1016/j.ahj.2012.09.009
NLM
Feres F, Costa RA, Bhatt DL, Leon MB, Botelho RV, King SB, Paula JET de, Mangione JA, Salvadori Júnior D, Gusmão MO, Castello Júnior H, Nicolela Júnior E, Perin MA, Devito FS, Marin Neto JA, Abizaid A. Optimized duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (optimize) trial: rationale and designof a large-scale, randomized, multicenter study [Internet]. American Heart Journal. 2012 ; 164( 6): 810-816.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ahj.2012.09.009
Vancouver
Feres F, Costa RA, Bhatt DL, Leon MB, Botelho RV, King SB, Paula JET de, Mangione JA, Salvadori Júnior D, Gusmão MO, Castello Júnior H, Nicolela Júnior E, Perin MA, Devito FS, Marin Neto JA, Abizaid A. Optimized duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (optimize) trial: rationale and designof a large-scale, randomized, multicenter study [Internet]. American Heart Journal. 2012 ; 164( 6): 810-816.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ahj.2012.09.009
Artigo de periodico
Risk factors and outcomes for patients with vascular disease and serious bleeding events (2011)
Alberts, Mark J.; Bhatt, Deepak L.; Smith Jr., Sidney C.; Röther, Joachim; Goto, Shinya; Hirsch, Alan T.; Steg, Gabriel; Pazin Filho, Antonio
Source: Heart. Unidade: FMRP
Subjects: DOENÇAS VASCULARES, FATORES DE RISCO, HEMORRAGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALBERTS, Mark J. et al. Risk factors and outcomes for patients with vascular disease and serious bleeding events. Heart, v. 97, n. 18, p. 1507-1512, 2011Tradução . . Disponível em: https://doi.org/10.1136/hrt.2010.221788. Acesso em: 10 nov. 2024.
APA
Alberts, M. J., Bhatt, D. L., Smith Jr., S. C., Röther, J., Goto, S., Hirsch, A. T., et al. (2011). Risk factors and outcomes for patients with vascular disease and serious bleeding events. Heart, 97( 18), 1507-1512. doi:10.1136/hrt.2010.221788
NLM
Alberts MJ, Bhatt DL, Smith Jr. SC, Röther J, Goto S, Hirsch AT, Steg G, Pazin Filho A. Risk factors and outcomes for patients with vascular disease and serious bleeding events [Internet]. Heart. 2011 ; 97( 18): 1507-1512.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/hrt.2010.221788
Vancouver
Alberts MJ, Bhatt DL, Smith Jr. SC, Röther J, Goto S, Hirsch AT, Steg G, Pazin Filho A. Risk factors and outcomes for patients with vascular disease and serious bleeding events [Internet]. Heart. 2011 ; 97( 18): 1507-1512.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/hrt.2010.221788
Artigo de periodico
The reduction of atherothrombosis for continued health (REACH) registry: an international, prespective, observational investigation in subjects at risk for atherothrombotic events-study design (2006)
Ohman, E. Magnus; Bhatt, Deepak L.; Steg, Gabriel; Goto, Shinya; MedSci, D.; Hirsch, Alan T.; Mas, Jean-Louis; Richard, Alain-Jean; Röther, Joachim; Wilson, Peter W. F.; Maciel, Léa Maria Zanini; Pazin Filho, Antonio
Source: American Heart Journal. Unidade: FMRP
Subjects: DOENÇAS VASCULARES, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OHMAN, E. Magnus et al. The reduction of atherothrombosis for continued health (REACH) registry: an international, prespective, observational investigation in subjects at risk for atherothrombotic events-study design. American Heart Journal, v. 151, p. 786.e1 - 786.e10, 2006Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2005.11.004. Acesso em: 10 nov. 2024.
APA
Ohman, E. M., Bhatt, D. L., Steg, G., Goto, S., MedSci, D., Hirsch, A. T., et al. (2006). The reduction of atherothrombosis for continued health (REACH) registry: an international, prespective, observational investigation in subjects at risk for atherothrombotic events-study design. American Heart Journal, 151, 786.e1 - 786.e10. doi:10.1016/j.ahj.2005.11.004
NLM
Ohman EM, Bhatt DL, Steg G, Goto S, MedSci D, Hirsch AT, Mas J-L, Richard A-J, Röther J, Wilson PWF, Maciel LMZ, Pazin Filho A. The reduction of atherothrombosis for continued health (REACH) registry: an international, prespective, observational investigation in subjects at risk for atherothrombotic events-study design [Internet]. American Heart Journal. 2006 ; 151 786.e1 - 786.e10.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ahj.2005.11.004
Vancouver
Ohman EM, Bhatt DL, Steg G, Goto S, MedSci D, Hirsch AT, Mas J-L, Richard A-J, Röther J, Wilson PWF, Maciel LMZ, Pazin Filho A. The reduction of atherothrombosis for continued health (REACH) registry: an international, prespective, observational investigation in subjects at risk for atherothrombotic events-study design [Internet]. American Heart Journal. 2006 ; 151 786.e1 - 786.e10.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/j.ahj.2005.11.004

USP Schools

ReP

Filtros

Authors

Date published

Subjects

Source title

Indexado em

Non normalized affiliation